All News

2061 articles, sorted by publication time.

Clinical Trials · global

Follow-up Extended to 84 Weeks: Pasatru Provides Evidence of Sustained Control in a Rare Ossification Disorder

In patients with FOP, abnormal bone gradually forms in soft tissues. The OPTIMA extension trial showed no new ossification lesions detected in the Pasatru treatment groups from weeks 56 to 84, but the higher dose was associated with more skin and soft tissue infections. Long-term benefits still need to be weighed alongside the risks.

Biotechnology Industry · global

Intercepting Disease-Causing Proteins Before They Take Shape: Pfizer Teams Up with Enodia to Develop Sec61 Small-Molecule Drugs

A collaboration with a potential total value exceeding $500 million is betting on an intracellular protein transport checkpoint. Whether this approach can selectively eliminate disease-causing proteins while preserving normal physiological functions will be key to its progress toward clinical development.